Abstract:Objective: To investigate expression of proliferating cell nuclear antigen (PCNA) in ovarian epithelial cancer and its relation to lymph node metastasis, outcome of second-look laparotomy (SLL) and prognosis. Methods: Monoclonal antibody PC10 was used to stain PCNA in archival paraffin-embedded tissues. Results: PC10 immunostaining was performed successfully in all 74 primary and 31 intraperitoneal metastatic tumors. The expression levels of PCNA were significantly increased in 31 metastatic tumors compared with their primary tumor from the same patients (7.94 vs 6.89,P=0.042). The expression levels was more elevated in bilateral than in unilateral ovarian cancer, but it was not associated with lymph node metastasis, clinical stage, histological grade and subtype. In 28 patients with stage III ovarian cancer undergone SLL, the mean immunoreactive score (IRS) of PCNA of the primary tumor was significantly higher in patients with negative SLL than in those with positive SLL (7.59 vs 6.10,P=0.03). Since chemotherapy was performed following surgical debulking, negative SLL more frequently seen in patients with high PCNA expression might suggest better chemotherapeutic sensitivity due to higher proliferation fraction of tumor cell. Univariate analysis of survival indicated that the overall survival was inversely associated with the level of PCNA expression, while multivariate analysis with Cox’s model showed that independent prognostic factors were the residual tumor after primary debulking (P<0.001) and clinical stage (P<0.05), followed by PCNA expression (P=0.09). Conclusion: The expression of PCNA may be useful in predicting the patients’ prognosis, but is not correlated with lymph node metastasis.

The clinical significance of the detection of PCNA in large intestine tumor

The Expression and Clinical Significance of PCNA and C-erbB-2 in Breast Cancer Tissue

Relationship Between Expression of Proliferating Cell Nuclear Antigen and Prognosis of Colorectal Cancer

Expression and Significance of PCNA Protein and MVD in Pancreatic Adenocarcinoma

The Expression of PCNA Protein and Its Relationship with Recurrence of Bladder Cancer

β-catenin and PCNA expression in gastric cancer tissues and their correlation with clinical prognosis

Expression of P53 and PCNA in gastric carcinoma detected by tissue microarray

Expression of proliferation cell nuclear antigen in bladder carcinoma and its clinical significance

Expression and Significance of P53 and Bcl-2 Protein Pancreatic Adenocarcinoma

Evaluation of Prognosis and Expression of PCNA in the Early Breast Cancer

Clinical Significance of Expression of PCNA in the Ovarian Epithelial Neoplasma

EXPRESSION AND PROGNOSTIC EVALUATION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER

Expression and clinical significance of proliferating cell nuclear antigen in patients with ovarian epithelial carcinoma

Expression of PCNA in Human Bladder Transitional Cell Carcinoma and Its Clinical Significance

Proliferating Cell Nuclear Antigen (PCNA) in Ovarian Carcinoma and Its Relation to Lymph Node Metastasis and Prognosis

Prognostic Evaluation of PCNA and BCL-2 Expression in Colorectal Carcinoma

The Expression of VASP and PCNA in Colorectal Adenocarcinomas

Expression and clinical significance of PCNA C-erbB-2 and nm-23-H1 in breast cancer tissues

Expression and significance of PTEN and PCNA in cervical squamous carcinoma tissue

Expression of CK20 and PCNA in Gastric Carcinoma and Its Clinical Significance

Relationship between the expression of mutant P53 and PCNA and their clinical significances in transitional cell carcinoma of the bladder